Figure 6.

TFH and TFR subsets were recovered in patients achieving stable remission from active stage. Peripheral blood were collected from 11 active UC patients who achieved stable remission after being treated with 5-ASA. (A,B) CD4⁺CXCR5⁺FoxP3⁺ TFR cells, CD4⁺CXCR5⁺FoxP3⁻ TFH cells, CD3⁺CD4⁺CXCR5⁺FoxP3⁻CXCR3⁻CCR6⁻TFH2 cells, CD3⁺CD4⁺CXCR5⁺FoxP3⁻CXCR3⁻ CCR6⁺ TFH17 cells, and Helios+ TFR cells were analyzed by flow cytometry and compared with their levels before treatment. (C) B cell subsets were analyzed by staining with CD19 CD24 and CD38 antibodies. Plasmablasts (CD19⁺CD38^highCD24⁻) and new memory B cells (CD19⁺CD24⁻CD38⁻) were calculated and compared with their levels before treatment.